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necrosis – 74,5% in 6 months observation time for each: HDR-
BT and PDR-BT method in h/n.  Serious late side-effects were 
seen in two patients (9%) - l/t and PDR-BT group.  
Conclusions: 1. HDR and PDR both had similar percentages of 
side effects. 2. Early complications due to the total radiation 
dose are frequent and needs to be treated by intensive 
pharmacology. 3. HDR or PDR are effective tools in tumor 
recurrence radiation treatment, when surgical procedure is 
impossible and using another EBRT schedule very dangerous 
for the patient.  4. Future studies should aim to determine 
the maximum tolerated dose and appropriate patient 
selection.   
Key words: head and neck cancer, HDR brachytherapy, PDR,  
recurrence, salvage treatment.   
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Purpose/Objective: Irresectable locoregional recurrent 
breast cancer in previously irradiated area is a life 
threatening disease and optimal treatment is still a matter of 
debate. Re-irradiation combined with hyperthermia 
(reRT+HT) is a valid treatment option. Four hundred and 
fourteen patients were treated with reRT+HT in the AMC 
(n=301) and the BVI (n=113), from January 1982 up to 
January 2006. We calculated response rates and local control 
(LC). Prognostic factors for tumor control were analysed in a 
multivariable analysis, with special emphasis on tumor size.  
Materials and Methods:  All patients previously received 
radiation, overlapping the current reRT field, to a median 
dose of 50Gy with or without boost. Median interval between 
initial treatment and reRT+HT was 54 months (range, 3-469). 
Most patients (80%) received one or more courses of systemic 
therapy in the past. 
The median age was 57 years at start of reRT+HT. The 
estimated tumour size was >10cm in 48% of patients (range 
0.2 – 26 cm). Distant metastases (DM) were present in 36% of 
patients and 74% had experienced previous recurrence 
episodes (range, 1-13). ReRT consisted typically of 8x4Gy, 
twice a week (AMC) or 12x3Gy, four times a week (BVI). 
Superficial hyperthermia was added once (ACM)/twice (BVI) a 
week using 434MHz Contact Flexible Microstrip Applicators. 
Aim temperature was 41-43°C for one hour. Twenty-two 
percent of patients received additional chemotherapy and 
30% additional hormone therapy. 
Results: Overall clinical response rate was 86% (58% cCR + 
28% cPR). Median follow-up (FU) 17 months. Median overall 
survival was 17 months. The 3-year LC rate was 25%. Tumor 
size, time interval to recurrence, the number of previous 
recurrent episodes, and prescence of DM were significant 
prognostic factors for LC. For patients with isolated 
locoregional recurrences ≤ 5 cm the 3-year LC rate was 47%.  
(Table.1).  
 
 
 
Conclusions: Re-irradiation combined with hyperthermia for 
locoregional recurrence after previous irradiation results in 
high response rates of 86%, despite resistance to previous 
treatments. Overall long-term LC control was 25%, but up to 
47% in smaller tumors (< 5cm.). Tumor size, and absence of 
DM were positive prognostic factors for LC duration and 
overall survival. 
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Purpose/Objective: The outcome of current treatment of 
locally-advanced and recurrent head and neck carcinoma 
(HNC) in patients treated with radiotherapy alone is 
disappointing. The combination treatment of radiotherapy 
(RT) and cisplatin or cetuximab improves survival. Increased 
toxicity and comorbidity prohibiting combined treatment 
with cisplatin or cetuximab warrant the need for another 
radiosensitizer. Stimulated by several randomised studies 
demonstrating the radio-sensitizing effect of hyperthermia, 
we developed the HYPERcollar for applying deep 
hyperthermia in the HNC region. Here, we report the early 
experience and toxicity of deep hyperthermia treatment 
combined with radiotherapy in a cohort of patients with 
advanced HNC. 
Materials and Methods: In total, 119 hyperthermia 
treatments given to 27 patients, treated with advanced HNC, 
were included in this analysis. Hyperthermia was applied for 
60 minutes, or later 75 minutes, depending on patients’ 
tolerance using the HYPERcollar, aimed at achieving 43°C in 
the target region. Treatment quality was monitored by 
patient specific hyperthermia pre-treatment planning 
combined with real-time invasive thermometry if possible, or 
pre-treatment planning alone. RT was given using either 
external beam irradiation (Cyberknife or IMRT) or interstitial 
irradiation. 
Results: Applying hyperthermia in the very well perfused 
head and neck region proved to be challenging and high 
power levels were required (median 543W). 13% of the 
hyperthermia treatments were not fully completed, mostly 
due to pain (5%), which we allocated to hyperthermia 
treatment and dyspnoea (2%) caused by sticky saliva, 
associated with irradiation. Mean hyperthermia treatment 
time was 94% of planned duration. No severe complications 
or enhanced thermal or mucosal toxicities were observed. 
Preferably, metal implants (>1cm) should be removed to 
minimize the risk of toxicity, and prevent any unpredictable 
resonances reducing the predictive value of treatment 
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planning. After 3 months a complete response was observed 
in 46%, and 7% had partial response.  
Conclusions: Using the HYPERcollar, deep hyperthermia 
treatment of HNC was found to be safe, feasible, with good 
compliance and promising outcome. These promising early 
clinical results culminated in the use of hyperthermia as a 
standard addition to reirradiation. We will now embark on a 
study for (chemo-)irradiation combined with hyperthermia in 
primary head and neck cancer.  
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Randomized controlled trials (RCTs) are the gold standard for 
comparative effectiveness research of medical interventions. 
Treatment guidelines rank evidence of using a hierarchy with 
evidence from RCTs at the highest level, Level I. Many 
authorities require Level I evidence from RCTs for 
registration and reimbursement of a new drug. When Level I 
evidence is not available, the treatment is often viewed as 
being “unproven”. Ideally, every new diagnostic or 
interventional procedure should be tested in RCTs before 
becoming standard care to avoid ineffective or harmful 
treatments. The reason is that even treatments supported by 
a clear biological rationale and strong pre-clinical data may 
not produce a therapeutic gain; examples include the 
detrimental effect of erythropoietin when used together with 
radiotherapy for head and neck cancer  or class 1c 
antiarrhythmic agents in myocardial infarction patients . The 
unexpected result of these studies provides a strong 
argument in favour of randomization.   
Engineers and physicists often tackle the problem of 
obtaining “evidence” by making models to calculate the 
quantitative relationship between parameters and a 
particular outcome. The acceptance of the latter kind of 
empirical model spring from its ability to predict the 
outcome of experiments with accuracy, reliability and 
prospective reproducibility that is sufficient to be useful. The 
analogy with human biology is far from perfect because of 
the complexity of the processes involved. In physics 
controlling a rather limited set of known experimental 
conditions will suffice to standardize outcome 
measurements. The utility of models predicting clinically 
relevant outcomes could theoretically indeed be established 
by prospective comparisons between expected and observed 
outcomes. However, this is no simple task and has not been 
accomplished convincingly in the past. Nearly all proton 
therapy studies are retrospective, with heterogeneous 
patient groups recruited over long time periods, treated with 
varying techniques and with often very incomplete follow-up 
data. The radiobiology of the complex DNA damage in the 
Bragg peak is large unexplored and is not taken into account 
in current proton TPS. Some TCP and NTCP models are 
without doubt of merit for photon therapy, but they should 
not be extrapolated blindly to proton therapy as long as the 
latter models too have undergone extensive validation. The 
model-based approach is clearly a field where much more 
research is needed before this can be accepted as an 
alternative for RCTs. Except for some quite extreme cases, 
e.g. in some CNS and childhood tumours, randomised trials 
are still necessary, scientifically, legally and for obtaining 
reimbursement.   
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Purpose / Objective: Cognitive impairment is frequently 
present in childhood brain tumour survivors and greatly 
impacts psychosocial development and quality of survival. 
Major contributing factors are related to tumour, the 
presence of hydrocephalus, surgery, chemotherapy and 
radiotherapy. The neurocognitive functions primarily involved 
are including memory, attention, visual perceptual ability 
and verbal function.  
Materials and Methods: The majority of data are essentially 
based on past treatments with varying treatment volumes 
(craniospinal irradiation followed by a boost, whole brain 
irradiation, local irradiation with varying dose prescriptions) 
for medulloblastoma, low grade glioma, ependymoma, germ 
cell tumours and leukemia. The literature is replete of data 
based on retrospective evaluations spanning many years 
during which general disease management was improved. 
Additionally, radiotherapeutic approaches considerably 
changed with the introduction of 3 D conformal technologies 
including IMRT and recently proton therapy that essentially 
permit a more precise coverage of tumour while sparing 
normal brain tissue.  
Results: Post radiation changes include a wide spectrum of 
abnormalities from subclinical changes detectable only by 
MRI to focal neurological deficits and intellectual 
impairment. It appears that all changes are likely to result 
from complex alterations within several functional 
compartments with the following contributing factors: 
damage to vessel structures, deletion of oligodendrocyte 
progenitor cells and mature oligodendrocytes (white matter), 
deletion of neural stem cell population in the hippocampus. 
Additionally, the tumours significantly differ between the 
inherent disabling potential with respect to tumour location 
and the therapeutic approach. The major risk factors are 
young age at treatment and a dose relationship in whole 
brain irradiation. Recent data indicate that particular 
radiosensitive regions of the brain are more susceptible to 
the adverse effects of radiation such as frontal lobes, 
temporal lobe and hippocampus including anatomical 
subcompartments in which neurogenesis occurs 
(subventricular zone). However, the relationship between 
radiation dose to these areas and a decline in neurocognitive 
function remains a controversial issue. Recent data indicate 
that radiation dose to neuronal progenitor cell niches and 
temporal lobes causes a decline in cognitive function. Modern 
radiotherapy technologies are able to selectively reduce the 
dose to organs at risk. Correspondingly, reducing the dose to 
the hippocampus in adults appears to preserve memory with 
conformal avoidance of the hippocampal neural stem cell 
compartment during whole-brain radiotherapy (recently 
